Health Care • Misc Health and Biotechnology Services
$17.74 ▼ -0.41
(-2.26%)
MKT CAP: $5.18B • VOL: 3.19M
52W L $13 52W H $20
SHC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.16B | $1.10B | $1.05B |
| YoY Revenue Growth % | +5.7% | +4.9% | — |
| Gross Profit | $645.5M | $602.3M | — |
| Gross Margin % | 55.5% | 54.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $92.0M | $297.6M | $276.7M |
| Operating Margin % | 7.9% | 27.0% | 26.4% |
| Net Income (GAAP) | $77.9M | $44.4M | $51.4M |
| EBITDA (Normalized) | $202.4M | $440.9M | $314.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $287.2M | $224.2M | -$147.7M |
| Capital Expenditures (CapEx) | $138.0M | $179.1M | $47.2M |
| Free Cash Flow (FCF) | $149.2M | $45.1M | -$194.9M |
| FCF Margin % | 12.8% | 4.1% | -18.6% |
| Return on Invested Capital (ROIC %) | 3.0% | 10.1% | 12.3% |
| Cash & Short-Term Equivalents | $344.6M | $277.2M | — |
| Total Debt (Short + Long Term) | $2.13B | $2.21B | $686.8M |
| Total Stockholders' Equity | $606.0M | $404.9M | $1.41B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SHC.